These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 32096610)

  • 1. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
    Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
    Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
    Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
    Byeon S; Cho JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Tasaka Y; Honda T; Nishiyama N; Tsutsui T; Saito H; Watabe H; Shimaya K; Mochizuki A; Tsuyuki S; Kawahara T; Sakakibara R; Mitsumura T; Okamoto T; Kobayashi M; Chiaki T; Yamashita T; Tsukada Y; Taki R; Jin Y; Sakashita H; Natsume I; Saitou K; Miyashita Y; Miyazaki Y
    Lung Cancer; 2021 May; 155():120-126. PubMed ID: 33798901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.
    Zamora C; Riudavets M; Anguera G; Alserawan L; Sullivan I; Barba A; Serra J; Ortiz MA; Gallardo P; Perea L; Gavira J; Barnadas A; Majem M; Vidal S
    Cancer Immunol Immunother; 2021 Jun; 70(6):1691-1704. PubMed ID: 33388994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients.
    Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
    Anticancer Drugs; 2020 Sep; 31(8):872-875. PubMed ID: 32796406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
    Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
    Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab.
    Yamaguchi O; Kaira K; Shinomiya S; Mouri A; Hashimoto K; Shiono A; Miura Y; Akagami T; Imai H; Kobayashi K; Kagamu H
    Thorac Cancer; 2021 Feb; 12(3):304-313. PubMed ID: 33185333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
    Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
    Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
    Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
    Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.